Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15701MR)

This product GTTS-WQ15701MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Macular edema following Central Retinal Vein Occlusion (CRVO), Diabetic retinopathy research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ15701MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12393MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NEOD-001
GTTS-WQ9930MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KB-004
GTTS-WQ77MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ12238MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ4142MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BI-754091
GTTS-WQ7312MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FPA-144
GTTS-WQ207MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ377MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 20D7S
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW